2017 ESMO Congress
Bonnie S. Glisson, MD, on HPV-16+ Cancer: Study Results
Bonnie S. Glisson, MD, of The University of Texas MD Anderson Cancer Center, discusses a clinical trial on the combination of ISA101, an HPV-16 vaccine, and nivolumab for patients with incurable HPV-1...
Judy E. Garber, MD, MPH, on Triple-Negative Breast Cancer: An Update
Judy E. Garber, MD, MPH, of Dana-Farber Cancer Institute, offers expert perspectives on the role of PARP inhibitors in treating triple-negative breast cancer.
Toni K. Choueiri, MD, on RCC: Results From the CABOSUN Trial
Toni K. Choueiri, MD, of Dana-Farber Cancer Institute, discusses updated overall survival results on cabozantinib vs sunitinib as initial targeted treatment for patients with metastatic renal cell car...
Luis G. Paz-Ares, MD, PhD, on NSCLC: Results of the PACIFIC Trial
Luis G. Paz-Ares, MD, PhD, of Hospital Universitario 12 De Octubre, discusses phase III study findings on durvalumab after chemoradiation therapy in patients with stage III, locally advanced, unresect...
Eric Pujade-Lauraine, MD, PhD, on Ovarian Cancer: Results From the SOLO2 Trial
Eric Pujade-Lauraine, MD, PhD, of the Université Paris Descartes, discusses phase III study findings on the efficacy of olaparib maintenance therapy in patients with platinum-sensitive relapsed ovaria...
Michèle Beau-Faller, MD, PhD, on NSCLC: Biomarker Findings From the French Cooperative Thoracic Intergroup
Michèle Beau-Faller, MD, PhD, of the Hôpital de Hautepierre & Institut Régional du Cancer, discusses study results on ultrasensitive detection of EGFR T790M mutation by droplet digital PCR in TKI ...
Jeffrey S. Weber, MD, PhD, on Melanoma: Results of the CheckMate 238 Trial
Jeffrey S. Weber, MD, PhD, of New York University’s Langone Medical Center, discusses study results on adjuvant therapy with nivolumab vs ipilimumab after complete resection of stage III/IV melanoma (...
Bernard J. Escudier, MD, on RCC: Expert Perspective on Key Papers
Bernard J. Escudier, MD, of Gustave Roussy, offers a roundup of the important papers on renal cell cancer presented at this year's ESMO Congress.
Cora N. Sternberg, MD, on Prostate Cancer Treatment Findings: Expert Perspective
Cora N. Sternberg, MD, of the San Camillo Forlanini Hospital, summarizes a session on the STAMPEDE and LATITUDE trials, as well as a third trial on docetaxel with androgen suppression for localized pr...
Domenica Lorusso, MD, PhD, on Cervical Cancer: Results From a Trial on Treatment Regimens
Domenica Lorusso, MD, PhD, of the National Cancer Institute of Milan, discusses neoadjuvant chemotherapy followed by surgery vs concurrent cisplatin and radiation therapy in patients with stage IB2 to...
Robert A. Figlin, MD, on RCC: Results From the ADAPT Trial
Robert A. Figlin, MD, of Cedars-Sinai Medical Center, discusses an interim analysis of phase III findings on rocapuldencel-T, an individualized immunotherapy, for newly diagnosed patients with metasta...
Bernard J. Escudier, MD, on RCC: Results From the CheckMate 214 Trial
Bernard J. Escudier, MD, of Gustave Roussy, discusses efficacy and safety of nivolumab plus ipilimumab vs sunitinib for treatment-naïve advanced or metastatic renal cell carcinoma, including IMDC risk...
Karl D. Lewis, MD, on Melanoma: Results From the BRIM8 Trial
Karl D. Lewis, MD, of the Anschutz Cancer Pavilion, discusses study findings on adjuvant vemurafenib in patients with completely resected BRAF V600–positive melanoma at high risk for recurrence (Abstr...
Andrew R. Clamp, PhD, on Gynecologic Cancers: Results of the ICON8 Trial
Andrew R. Clamp, PhD, of The Christie NHS Foundation Trust, discusses his phase III study findings on dose-dense chemotherapy integration in first-line treatment of epithelial ovarian, fallopian tube,...
Sandro Pignata, MD, PhD, on Ovarian and Related Gynecologic Cancers: Expert Perspective on Three Key Trials
Sandro Pignata, MD, PhD, of the Istituto Nazionale dei Tumori, summarizes findings from the ICON8 study on dose-dense chemotherapy integration in first-line epithelial ovarian/fallopian tube/primary p...
Simone Koole, MD, on Ovarian Cancer: Results of the OVHIPEC Trial
Simone Koole, MD (and a PhD candidate), of the Netherlands Cancer Institute, discusses phase III findings on health-related quality of life after hyperthermic intraperitoneal chemotherapy for stage II...
Caroline Robert, MD, PhD, on Melanoma: Treatment With Nivolumab and Ipilimumab
Caroline Robert, MD, PhD, of Gustave Roussy, characterizes complete responses in patients with advanced melanoma who received the combination of nivolumab and ipilimumab, or nivolumab or ipilimumab al...
Marleen Kok, MD, PhD, on Triple-Negative Breast Cancer: Results From the TONIC Trial
Marleen Kok, MD, PhD, of The Netherlands Cancer Institute, discusses findings from an adaptive phase II noncomparative trial of nivolumab after induction treatment in triple-negative breast cancer (Ab...
Manuel Hidalgo, MD, PhD, on Biliary Tract Cancer: Results From the PRODIGY 12-ACCORD 18 Trial
Manuel Hidalgo, MD, PhD, of Harvard Medical School, discusses updated phase III findings on relapse-free survival and first overall survival results in adjuvant GEMOX (gemcitabine plus oxaliplatin) fo...
Robert I. Haddad, MD, on Head and Neck Cancer: Results of the CheckMate 141 Trial
Robert I. Haddad, MD, of Dana-Farber Cancer Institute, discusses phase III study results on treatment beyond disease progression with nivolumab in patients with recurrent or metastatic squamous cell c...
Jaafar Bennouna, MD, on Colorectal Cancer: Clinical Trial Findings on Targeted Treatments and Chemotherapy
Jaafar Bennouna, MD, of the University of Nantes, discusses findings from a phase II French study of bevacizumab or cetuximab plus chemotherapy after progression with bevacizumab plus chemotherapy in ...
David A. Tuveson, MD, PhD, on Progress in Pancreatic Cancer: Expert Perspective
David A. Tuveson, MD, PhD, of Cold Spring Harbor Laboratory, discusses the most lethal of cancers. Although treatments are improving, the challenges are great, including early detection of this malign...
Luis G. Paz-Ares, MD, PhD, on NSCLC: Results of the PACIFIC Trial
Luis G. Paz-Ares, MD, PhD, of Hospital Universitario 12 De Octubre, discusses phase III study findings on durvalumab after chemoradiation therapy in patients with stage III, locally advanced, unresect...
Sibylle Loibl, MD, PhD, on Metastatic Breast Cancer: Expert Perspective on CDK4 Inhibitors
Sibylle Loibl, MD, PhD, of the German Breast Group, summarizes a session she chaired in which the rationale to target CDK4, data on efficacy of the inhibitors, and triple combination therapy with PI3K...
Mansoor Mirza, MD: Ovarian Cancer Treatment and Quality of Life
Mansoor Mirza, MD, of Copenhagen University Hospital, discusses quality of life in patients with recurrent ovarian cancer treated with niraparib (Abstract 930O).
